San Francisco, CA (PressExposure) July 20, 2012 -- Lennart Mucke, Director at the Gladstone Institute of Neurological Disease and a Professor at UCSF will give a presentation on "Experimental Strategies to Prevent and Reverse Neural Network Dysfunction in Alzheimer's Disease" at the 6th Neurodegenerative Conditions Research and Development conference taking place on Sept 13-14, 2012 in San Francisco, CA.
In 1996, Dr. Mucke was recruited to head a program in molecular neurobiology at the Gladstone Institutes and the University of California, San Francisco (UCSF). The progress made resulted in the establishment of the Gladstone Institute of Neurological Disease, which he has directed since its inauguration in 1998. Dr. Mucke is the first holder of the Joseph B. Martin Distinguished Professorship in Neuroscience at UCSF, where he has joint appointments in the Department of Neurology and in the Neuroscience, Biomedical Sciences, and Medical Scientist (MD/PhD) Graduate Training Programs. He also teaches as an attending physician in neurology at San Francisco General Hospital.
Dr. Mucke's research focuses on processes that result in memory loss and other major neurological deficits, with an emphasis on Alzheimer's disease and related disorders. He has generated informative experimental models of these conditions and used them to identify novel strategies to prevent neurological decline. As the director of the Gladstone Institute of Neurological Disease, he has established a vigorous interdisciplinary program for research and training in disease-focused neuroscience.
GTC's 6th Neurodegenerative Conditions Research and Development conference brings together leading scientists and experts to discuss the latest breakthroughs, new drug targets, new models, the development of new biomarkers, imaging modalities, and several other novel developments and therapeutics to combat neurodegenerative conditions. The conference is also a part of the 2nd CNS Diseases World Summit, which has four parallel tracks that focus on neurodegenerative conditions, neuropsychiatric disorders, pain research and therapeutics and CNS partneriing and deal-making.
Hear from and meet with key representatives in the field including Charles B. Nemeroff at the University of Miami, Husseini Manji - Global Head of Neuroscience Therapeutic at Janssen, Stephen Brannan - VP at Takeda, Barry Brand - Chief Executive Officer at CeNeRx, Michael W. Weiner at UCSF, George Garibaldi - SVP and Global Head of Neuroscience Development at F. Hoffmann-La Roche, Marcelle Bergeron at Elan, Beth J. Hoffman - VP at Targacept, Li Gan at Gladstone Institute, and many more!
For more information, please visit http://www.gtcbio.com